Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: Real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment project

Hashimoto, Naoki; Yasui-Furukori, Norio; Hasegawa, Naomi et al.

Asian Journal of Psychiatry, 2021, 63, 102744

Permalink : https://hdl.handle.net/2115/82981

このアイテムのアクセス数:502件（2026-08-08 12:49 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
https://doi.org/10.1016/j.ajp.2021.102744     7

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
open access
URI
https://hdl.handle.net/2115/82981
タイトル
Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: Real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment project
著者
Hashimoto, Naoki ; Yasui-Furukori, Norio ; Hasegawa, Naomi ; Ishikawa, Shuhei ; Numata, Shusuke ; Hori, Hikaru ; Iida, Hitoshi ; Ichihashi, Kayo ; Furihata, Ryuji ; Murata, Atsunobu ; Tsuboi, Takashi ; Takeshima, Masahiro ; Kyou, Yoshitaka ; Komatsu, Hiroshi ; Kubota, Chika ; Ochi, Shinichiro ; Takaesu, Yoshikazu ; Usami, Masahide ; Nagasawa, Tatsuya ; Hishimoto, Akitoyo ; Miura, Kenichiro ; Matsumoto, Junya ; Ohi, Kazutaka ; Yamada, Hisashi ; Inada, Ken ; Watanabe, Koichiro ; Shimoda, Kazutaka ; Hashimoto, Ryota
著者名
Hashimoto, Naoki
著者名
Yasui-Furukori, Norio
著者名
Hasegawa, Naomi
著者名
Ishikawa, Shuhei
著者名
Numata, Shusuke
著者名
Hori, Hikaru
著者名
Iida, Hitoshi
著者名
Ichihashi, Kayo
著者名
Furihata, Ryuji
著者名
Murata, Atsunobu
著者名
Tsuboi, Takashi
著者名
Takeshima, Masahiro
著者名
Kyou, Yoshitaka
著者名
Komatsu, Hiroshi
著者名
Kubota, Chika
著者名
Ochi, Shinichiro
著者名
Takaesu, Yoshikazu
著者名
Usami, Masahide
著者名
Nagasawa, Tatsuya
著者名
Hishimoto, Akitoyo
著者名
Miura, Kenichiro
著者名
Matsumoto, Junya
著者名
Ohi, Kazutaka
著者名
Yamada, Hisashi
著者名
Inada, Ken
著者名
Watanabe, Koichiro
著者名
Shimoda, Kazutaka
著者名
Hashimoto, Ryota
言語
英語
キーワード
Antipsychotics
Antidepressants
Monopharmacy
Polypharmacy
EGUIDE
発行日
2021-09
出版者
Elsevier
収録物名
Asian Journal of Psychiatry
巻(号)
63
ページ
102744
抄録
Background: Monopharmacy with antipsychotics and antidepressants is the first-line treatment for schizophrenia and major depressive disorder (MDD) in most clinical guidelines, while polypharmacy with psychotropic agents in the treatment of schizophrenia is common in clinical practice. There are no detailed data on the prescription patterns for inpatients with mental illness with reliable diagnoses made by treating psychiatrists. Methods: We gathered prescription data at discharge from 2177 patients with schizophrenia and 1238 patients with MDD from October 2016 to March 2018. Results: The patients with schizophrenia aged between 60 and 79 were prescribed lower doses of antipsychotics and hypnotics/anxiolytics than those aged between 40 and 59. There were significant differences between the prescription rate of antipsychotics in the patients with schizophrenia and that of antidepressants in the patients with MDD. The frequency of concomitant drugs such as anti-Parkinson drugs, anxiolytics/hypnotics and mood stabilizers in the subjects with schizophrenia prescribed antipsychotic polypharmacy was significantly higher than that with monotherapy. For the patients with schizophrenia, olanzapine, risperidone, aripiprazole, quetiapine, and blonanserin were the five most prescribed antipsychotics. For the patients with MDD, mirtazapine, duloxetine, escitalopram, trazodone and sertraline were the five most prescribed antidepressants. Conclusions: Our results showed the use of high doses of antipsychotics, high percentages of antipsychotic polypharmacy and concurrent use of hypnotics/anxiolytics in patients with schizophrenia. Notably, these data were collected before intensive instruction regarding the guidelines; therefore, we need to assess the change in the prescription pattern post guideline instruction.
資源タイプ
学術雑誌論文
出版タイプ
Version of Record
PISSN
1876-2018
関連情報 (isIdenticalTo)
出版社版DOI
https://doi.org/10.1016/j.ajp.2021.102744